Nufarm Limited (NUF) Earnings Call Transcript & Summary

May 18, 2023

Australian Securities Exchange AU Materials Chemicals earnings 77 min

Earnings Call Speaker Segments

Operator

operator
#1

Good day, and thanks for joining the Nufarm conference call on our first half 2023 results. Please be aware that this session is being recorded. Appreciate it. At this point, I'm pleased to hand things over to Greg Hunt, our CEO, to open the conference. Greg, the floor is yours.

Greg Hunt

executive
#2

Thanks, Connie. Morning, everyone. Welcome, and thanks for being with us today. On today's call I'm joined by our CFO, Paul Townsend, and we also have Rico Christensen and Brent Zacharias with us — they'll use this opportunity to give an update on the progress we've made in the half towards our longer-term growth aspirations. Before we begin, I'd like to point you to the disclaimer on page 3, in particular the section covering forward-looking statements. I'm happy to report a strong result and a positive start to the financial year for Nufarm. Revenue and EBIT were relatively steady, while our underlying net profit rose by 7%. We delivered underlying EBITDA of AUD 316 million. That's an excellent result given we're coming off a record year, and I'm pleased to say we're on track to meet our full-year earnings guidance. Importantly, during the period we made progress and remain on track to meet the key milestones we've committed to as we work towards our FY26 growth aspirations. Given the strong result and positive outlook, we're pleased to announce an increase in the interim dividend to AUD 0.05 a share. A number of factors are driving our performance.

Greg Hunt

executive
#3

A range of new products rolled out across our crop protection platforms, and those launches helped drive the gross margin improvement. That's a key element of what we're aiming for in terms of growth. As mentioned before, Rico will go into more detail on those launches and on how healthy our pipeline is overall. Seed technologies posted a very strong result, with revenue up 25% and earnings up 34%. Thanks to the strong contribution from seeds and a better product mix across the portfolio, gross profit margins have expanded by 120 basis points in the first half. We've reported higher inventories and working capital, especially in North America. We expect inventory to come down in the second half as more traditional supply-demand patterns return. We also anticipate leverage will be within the targeted range of 1.5x-2x net debt to EBITDA by the 30th of September 2023. Our balance sheet is robust and remains flexible. Favorable seasonal conditions have been seen in most of the key markets where we operate, and we're seeing good demand for our seed and crop protection solutions in early second half trading. We remain on track to deliver modest earnings growth for the full year.

Greg Hunt

executive
#4

Turning to the following slide. As you can see here, substantial progress has been achieved, and we keep reaching important milestones while carrying out our strategic objectives. Crop protection, which I referenced earlier, is gaining from effective product introductions and is powered by solid ties with our technology partners. Our commercial relationship with Sumitomo stays robust, and the renewal of every one of our marketing and distribution agreements is now finished. Our seed technologies platforms keep advancing, with new hybrids delivering growth in multiple markets. We are also making good headway toward supplying at least 16,500 metric tons of our Omega-3 Canola oil from 2023 crop plantings. One very encouraging item during the period was the announcement that the Norwegian Scientific Committee for Food and Environment issued a favorable recommendation concerning Canola oil enriched with Omega-3 for fish feed. Norway's aquaculture market ranks as the biggest worldwide, so this offers an extremely sizable potential opportunity and marks another milestone accomplishment toward our growth plans. In the same way, our bioenergy ambitions stay on track, as we made our initial shipment of Carinata oil under the long-term supply agreement with BP. Just as we projected in November, we are striving toward our target of doubling the hectares planted with Carinata in 2023.

Greg Hunt

executive
#5

Argentina has been dealing with drought. We're working on growing the area in other countries to offset any shortfall we might see in Argentina. To sum up, delivering on these milestones puts us in a strong position as we pursue our FY26 revenue aspirations. Now turning to segment results. This table is included because it gives you a straightforward look at how strong and diverse our business is. Our geographic footprint and the growing contribution from our seed technologies help us minimize risk and reduce volatility, while also giving us a clear platform for growth. Moving to Europe now, where we had a very positive result, with growth in revenue and earnings. That came despite a €17 million decrease in revenue from product deregistrations. New product introductions, organic growth, and better gross margins drove the performance, and a lot of this comes from the portfolio we acquired in 2018. We're still working through some challenges at our site in the U.K. That said, the CapEx program we announced in February of last year will progressively address these issues. We expect some benefit from the delayed season in North and Central Europe, with sales moving into the second half.

Greg Hunt

executive
#6

That said, drought conditions that are lingering in Spain will partially counterbalance this. We anticipate that deregistrations will hit revenue by an additional €4 million, bringing it to the €21 million already identified for the full year. Even so, we think we can make up for that revenue hit through what sits in our current portfolio, organic growth, and new product introductions. If seasonal conditions come in as normal, we remain on course to post a result marginally ahead of last year's. APAC had a solid first half, especially given the record contribution posted in the first half of last year. As we anticipated, revenue and earnings took a hit from some softening in active ingredient pricing, glyphosate in particular. As flagged at the full year, restocking happened at lower prices, which means no additional provisions were needed as of the 31st of March for inventory held on that date. Over the year, we brought a number of new and higher-margin products to market, and every one of them added positively to the result, and we would expect this to remain a continuing pattern in future periods as the portfolio's mix keeps shifting. Near term, we are observing ongoing favorable conditions with good early rainfall.

Greg Hunt

executive
#7

Those conditions, along with grain prices that are somewhat higher, mean demand for our crop protection products keeps holding up strongly, and how business is going right now matches what we saw at this same point a year ago. Now to North America, where the outcome was shaped by sales shifting out of the first half and into the second half, since customers shifted toward buying more in-season. Lower sales volumes left revenues 12% lower and inventories higher. Stronger sales of products carrying better margins lifted gross margins and went some way toward countering the drop in volume. Even so, the outlook is still very positive. USDA forecasts for 2023 indicate that corn, soybean, and wheat acres should all increase. On top of that, as of the 14th of May, 65% of corn, 49% of soybean, and 35% of the cotton crop had been planted. Conditions are still favorable, with soil moisture adequate to above adequate across 80% of the planted area. Together with the agreements we already have in place that cut our exposure to price volatility on lower-margin products, we feel confident about a strong second half in North America. Moving to Seed Technologies. Most of the points I wanted to raise there were really already covered in what I said earlier.

Greg Hunt

executive
#8

Even so, we're positioned to deliver a stronger second half, and let me just underline once more that Seed Technologies gives the company a genuinely exciting and meaningful platform for growth. This outcome extends the earnings momentum that keeps us on course to hit or beat our FY26 aspirations. Later in the presentation, Brent will cover our current programs along with our growth ambitions for the coming few years. At this point I'll pass things to Paul, who will walk you through the details and the financials. Thank you, Paul.

Paul Townsend

executive
#9

Thanks, Greg. Now I'll go into a bit more detail on the financial performance. Revenue is down slightly, by 1%, as Greg mentioned, while underlying gross profit margin rose 122 basis points, which reflects an improved sales mix, the launch of new higher-margin products across the regions, and a greater contribution from Seeds Technologies, which carries relatively higher gross margins. That's an excellent result given increases in manufacturing costs and manufacturing disruptions. While underlying gross profit is up 3%, underlying EBITDA of AUD 360 million is down 4% and reflects higher SG&A and R&D costs, of AUD 26 million and AUD 4 million respectively. The main SG&A cost impacts are an increase in headcount and other costs to support growth in the Seeds Technology segment, CPI and salary and incentive increases, higher freight and warehousing costs tied to holding larger inventory volumes, and more travel as we come out of COVID. Underlying EBIT of AUD 228 million is 3% higher than the corresponding period, reflecting lower depreciation amortization due to the phasing out of products and regulatory extensions to certain products in main Europe, together with delayed plant and equipment CapEx. Underlying NPAT is up 7%, reflecting the higher EBIT and lower effective tax rate despite higher financing costs.

Paul Townsend

executive
#10

Our underlying tax rate got better half on half, and that's because Nufarm kept delivering strong financial results, which let us recognize previously unbooked tax losses through the P&L. Underlying financing costs rose half-over-half, driven largely by higher floating-based interest rates on drawn debt facilities as well as higher drawn debt levels. Average net working capital sales remains under our target range of 33%, up 6 percentage points, though it's coming off an unusually low level of 27% in the first half of FY22. Net debt has climbed to AUD 1.04 billion, with leverage now sitting at 2.5 times, which mirrors the negative cash outflow for the half. We regard these debt levels and this leverage as temporary only, and we expect leverage to be below or within the target leverage range of 1.5 to 2 times by 30 September 2023. Basic earnings per share rose by AUD 0.02 per share, moving from AUD 0.34 to AUD 0.36 per share, and the board has declared a dividend of AUD 0.05 per share, up from AUD 0.04 per share in the prior corresponding period. Now turning to cash flow. Importantly, net working capital balances have stayed relatively low over the past two years, driven by lower inventory levels, which were affected by supply chain disruptions through the COVID period.

Paul Townsend

executive
#11

For the first half of 2023, net operating cash flow came in at negative AUD 559 million, and that was mainly a result of EBITDA along with the shift in net working capital. That net working capital movement plays a big part in shaping operating cash flow results — especially receivables movements and inventory growth. As this slide shows, operating cash flow in each half tends to be much lower and/or negative during the first half versus the second half, which mirrors the seasonal build and unwind of net working capital. Basically, receivable collections are higher in the second half than in the first because of how Nufarm's sales are seasonal. While seasonality does affect the current net working capital movement — producing higher net working capital in the first half than in the second — it has additionally been affected by the elevated stock levels Nufarm is holding, and more specifically, the higher stock levels in North America, along with receivables falling away at normally low levels in the second half of 2022. I'll now move to the following slide. It shows how the net working capital balance was composed across the last five halves. This slide demonstrates the way net working capital's composition shifts from one half to the next.

Paul Townsend

executive
#12

As I mentioned, the significant shift in the receivables balance from 1H 2022 to 2H 2022 led to unusually elevated collections of receivables—through customer prepayments and better collections—as customers worked to secure supply amid strained supply chains during that time. That point was emphasized when we reported the FY 2022 result. While this produced an outstanding net working capital result for financial year 2022, the reversion to a normal receivables level during the first half of 2023 has intensified the overall net working capital movement we reported in first half of 2023. In the second half of 2023, though, in line with earlier periods, we anticipate receivables will unwind compared with first half levels. For instance, applying a historical sales and collection profile could generate a movement, or cash inflow, of AUD 200 million-AUD 300 million in H2. The other major element of net working capital movements sits in our inventories. Inventory levels across FY 2021 and 1H 2022 were especially affected by COVID-related supply problems. Near the end of FY 2022, we managed to restock inventory and establish a safety buffer as supply chains began to loosen in order to support expected customer demand and make sure we were well covered before the season.

Paul Townsend

executive
#13

The inventory positions we carried through the first six months of 2023 are a product of those choices, though in North America they were also affected by customers deciding to delay purchases and move toward a more just-in-time approach rather than the advance ordering we saw during the previous two years. We stay confident that this is mostly a matter of timing and that inventory levels will come down, because agricultural fundamentals are still solid, soft commodity prices sit at or above their five-year averages, and U.S. planted acres are projected to rise, which should lead to more normalized buying patterns from customers. Importantly, we anticipate this net working capital level will decline as receivables and inventories are worked down, producing cash flow in H2 2023 that brings leverage to below or inside our target range of 1.5 times to 2 times by 30 September 2023. As an illustration, by May 16th we had already recorded a net decrease in group inventory of roughly AUD 120 million, a solid sign that inventory is moving toward where we want it at the close of the half. Regarding CapEx spending in the half, there are basically three components: investment CapEx, tangible spend, and property plant and equipment.

Paul Townsend

executive
#14

The investment CapEx includes a modest acquisition of a boom sprayer for our Croplands business in Australia. It also covers further investment in Encote, along with deferred consideration tied to the Biovertis and EasyCane acquisition. On the intangible or product investment side, the spend contains both a stay-in-business component and growth spending. Within crop protection, that covers spending tied to maintaining and defending product registrations, new products, and product enhancements. Seed technologies spending relates to new hybrids, registrations in new markets, and other regulatory investment. The property, plant, and equipment spend takes in a range of safety and environment initiatives as well as asset integrity investment, mostly in Wyke, aimed at improving the overall reliability and efficiency of our manufacturing facilities. Also included in that spend are further investments to expand capacity for Propionic and Preventol in Wyke, formulation improvements in Chicago Heights, and 2,4-D efficiency spending in APAC. As you may recall, we have earmarked circa AUD 100 million on top of normal maintenance or stay-in-business type CapEx across FY 2022 to FY 2024. All told, that is AUD 80 million to AUD 90 million per annum in property, plant, and equipment spend over that period. Labor shortages and raw material availability have for the most part delayed execution of these projects, and that will affect the overall timing of the initial FY 2022/2024 plan.

Paul Townsend

executive
#15

As a quick reminder, every dollar we put into growth gets evaluated against our capital management principles, and we look for a return that beats Nufarm's weighted average cost of capital. For the full year, we expect CapEx of roughly AUD 200 million to AUD 220 million, and that figure takes in AUD 30 million carried over from 2022. As I noted, net debt is now up at AUD 1.04 billion, and leverage sits at 2.0 times to 2.4 times net debt to EBITDA. As we said earlier, the rise in net debt stems largely from higher net working capital over the half, and we expect leverage to come back to within or under the target range of 1.5 times to 2 times as that net working capital unwinds during the second half. Turning to debt facilities, during the half we announced that Nufarm had signed a 5-year, $800 million revolving ABL credit facility secured against trade receivables and inventory. We have also put in place a smaller AUD 150 million liquidity facility that sits alongside the ABL facility and helps with the ongoing funding of Nufarm's working capital needs. Together with the $350 million senior unsecured notes issued in January 2022, these ABL facilities bring considerable benefits to Nufarm's capital structure, moving Nufarm to a covenant-like financing structure and lengthening the duration of the group's debt maturity profile.

Paul Townsend

executive
#16

As the group's net working capital balances rose during the half, Nufarm's fresh working capital debt facilities are fulfilling their purpose of supporting a flexible and resilient capital structure across operating cycles and fluctuating trading conditions. On liquidity, Nufarm can draw on undrawn debt facilities totaling AUD 319 million, along with access to cash of approximately AUD 348 million as at 31 March 2023. Given rises in base floating rates and higher average debt levels, interest expense is anticipated to climb in the second half of 2023 relative to. I'll now return the floor to Greg. Thanks, Paul. Before I pass things to Rico and Brent, I wanted to grab this quick moment to remind everyone of the wider macro trends and why we see this as an appealing industry. Agriculture provides the main source of food and so is essential to feeding a population that keeps growing. As the global population rises year after year, we must produce additional food to feed all of them. Crucially, technological and scientific progress has allowed farmers to boost their yields and cut waste, which matters greatly for satisfying the requirements of that expanding population. Simultaneously, mounting pressure exists to satisfy our food requirements in a more sustainable manner, and technological and scientific breakthroughs are transforming how we utilize land and plants to deliver food and nutrients.

Paul Townsend

executive
#17

Agriculture and oilseeds are also going to take on a growing role in energy production, since they'll be used as inputs for renewable fuels. When we use renewable fuels that carry sustainability certification, we cut our reliance on fossil fuels, bring greenhouse gas emissions down, and give farmers economic gains by opening up new crops or — sorry — by opening up new markets for the crops they grow.

Greg Hunt

executive
#18

Growing cover crops supports sustainable farming, locks away carbon, cuts erosion, and builds healthier soil. Nufarm sits at the leading edge of this shift. Much of that comes down to how we prioritize innovation and technology. Our view is that demand for what we make will keep rising, lifting both revenue and margins. That conviction is what fuels spending across our platforms and our ambitions for future growth. As I've noted previously, we still expect to hit or surpass those ambitions, first set out in February 2022. We are delivering against the major milestones that support those ambitions, and you'll now hear from Rico and Brent, who will walk you through more detail on what we've actually accomplished during the last few months. I'll turn things over first to Rico for crop protection.

Rico Christensen

executive
#19

Thanks, Greg. As Greg said earlier, Nufarm is both contributing to and gaining from the move toward more sustainable and innovative agricultural solutions. We're helping our growers get more output with fewer inputs, while offering products that assist them in adapting to climate change and reducing unintended environmental impacts. Sustainable growth at Nufarm will be driven by innovation and technology. We'll now update you on our development pipeline, which we presented at our Investor Day in February of 2022. Our pipeline will deliver across our core crops and our targeted geographies over multiple years, and it will keep strengthening how relevant we are to customers and support our revenue aspirations. During the past year, our product launches performed as planned. We remain on track to launch the scheduled new product introductions for financial year 23. The estimated market size of our top projects is AUD 6.65 billion. You may remember that the equivalent slide in February of 2022 showed 22 projects with a market size of AUD 6.6 billion. In the almost 18 months since then, certain projects have been launched in all markets and have therefore been successfully closed. Meanwhile, additional new projects have been brought in, including several that will be launched after 2026.

Rico Christensen

executive
#20

Moving to the next slide, I'll give you a few illustrations of product launches, but the main takeaway is that we remain on course to hit our 2026 ambition, and the pipeline beyond that also looks encouraging. In the first half, we brought a number of products to market. Keep in mind that our projects typically roll out in stages, since registrations don't arrive simultaneously in every country. A project stays active until it has launched in all of its target markets. For instance, we have now obtained the first registrations for Jaust, yet the project is still active because more launches are on the way. Five platforms make up our portfolio. The foundational products — Jaust, Galaxy, Terrad'or Flow, for example — are what we call the bread and milk. Farmers use them each season, and they matter enormously for solving critical economic problems. That said, as you're aware, we're putting growing investment into innovative solutions protected by IP. I'm happy to report that we've reached several significant milestones on those innovative solutions. We launched our own IP-protected DropZone in late 2022, and farmers throughout Australia responded incredibly positively. We also secured registrations and launched a new, an Anuew EC across North America together with a key research partner.

Rico Christensen

executive
#21

To wrap up, we lengthened the distribution arrangement for Terrad'or with FarmHannong, which is another key discovery partner of ours. Within the biological segment, we hit significant milestones as well. During the prior year, we brought our bionematicide Trunemco to market in the U.S. At this point we've also introduced it in Brazil alongside 3 distribution partners. For bionematicides, Brazil stands as the biggest and quickest-expanding market. That marked a major move for us. In Australia, we likewise released a new biofungicide called Intervene, created jointly with a strategic partner and already brought to market earlier in the U.S. Our new crop initiative with Crop.Zone has similarly advanced well through the first half. We've now named partners across several markets and are striving to bring on additional ones. Finally, I'd like to bring up Silicet, a biological pod shatter reduction product for canola that we built with yet another strategic partner. This offering will form part of the input platform we're putting together to serve the agronomic requirements of our Nuseed Omega-3 Canola and Carinata programs. Those are merely a handful of illustrations. As a matter of fact, our count of product lines has exceeded our count of product launches during the first half. I'd also like to point out that, broadly speaking, these newer products carry better margins, and because of that they helped drive the gain in average gross margin for the first half.

Rico Christensen

executive
#22

All in all, we feel very good about how the first half has gone, and as we said before, our pipeline remains on course to hit the 2026 ambition we've set.

Operator

operator
#23

Brent, I'll hand things over to you now.

Brent Zacharias

executive
#24

Thanks, Rico. As Greg mentioned, we're really happy with how the seed technologies results have come in. The innovation we're bringing to market is getting a strong response from customers. Across our three core seed positions — canola, sorghum, and sunflower — we significantly beat the prior period on both volume and revenue. We grew revenue and margins in the bioenergy and omega-3 platforms as well, compared with the prior period. This result shows the strength and synergy of all our technology platforms working together, the strong market adoption of those technologies, and the very clear trajectory we're on to meet or exceed our 2026 aspirational growth targets. Now, taking a closer look at what drove these first half results: our core seeds business continues to perform very strongly and remains the critical driver of our innovation, farm market presence, and capability that enables our Omega-3 nutrition and bioenergy growth platforms. A strong seeds capability is a precursor for success in our value beyond yield technologies. In the first half, Nuseed achieved additional market expansion in canola in Australia and Latin America South. We grew volumes in our sorghum markets in Brazil, the USA, and export markets, and we expanded our sunflower position in Southwest and Central Europe, the USA, and Latin America South, which more than offset our choice to reduce sunflower volumes in Eastern Europe due to the conflict.

Brent Zacharias

executive
#25

Looking at our Omega-3 platform, revenue and margin both increased compared with the prior year, driven by the ongoing advantages of scaled production and supply from Aquaterra. It's encouraging that customer adoption and support remain solid in Chile, our first market, and during the first half we recorded initial sales to aquaculture customers in North America. A planting trial in South Texas came off successfully, giving us an important extra winter production zone. Regarding regulation, as Greg noted, we achieved meaningful headway on the Norway approval we have planned, and I'll go into that in more depth shortly. We also advanced commercialization plans for Nutriterra, and momentum is building in food ingredients as well as in a high-value segment opportunity taking shape around concentrated oils. We have developed and been granted patents for the enrichment process, and have now commercially piloted it, to raise our oil to higher concentrations that the nutraceutical market is interested in. The first half brought a number of significant milestones for our bioenergy platform. After the first dedicated shipment of Nuseed Carinata to Saipol in Europe, BP took its initial oil deliveries under our strategic long-term offtake and market development agreement. Production expansion is ongoing, including new commercial-scale planting activity in the Southern U.S., and we delivered strong results from a new hybrid variety in a large-scale commercial harvest in Argentina, despite unusual drought and frost impacts.

Brent Zacharias

executive
#26

The energy cane technology we recently acquired has been brought into Nuseed's Brazilian business successfully, and we've put extra resources into R&D, agronomy, and commercial capabilities. Nuseed brought in its first energy cane revenues during the first half. Going forward, we're confident the drivers are there, internally and externally, to underpin strong growth in the periods ahead. On the seeds platform, that confidence rests on how resilient our core seeds positions are and on our capacity to grow revenues through the cycle, thanks to our higher value niche market positions, market shares that are strengthening, and a robust pipeline of new genetics and products. Our Omega-3 platform sits at a significant transition point, with greater scale and market expansion beginning in FY24 off the back of a larger FY23 planting, which will drive revenue and margin growth for AquaTerra, while new high-value market segments open up opportunities with Nutriterra. We're also still seeing trends toward sustainability, a tightening fish oil supply, and price appreciation. A very recent example of that: within the last 48 hours, the Peru Ministry made a public announcement that they have delayed and may reduce or possibly cancel first, the typically largest anchovy fishery quota. Turning back to Norway, although a number of key steps remain to be completed, we are making positive progress toward regulatory approval and market entry into Norway for AquaTerra.

Brent Zacharias

executive
#27

This is a step-by-step growth opportunity in the world's largest salmon farming market. We expect a final ruling from the Norwegian Food Safety Authority within this current calendar year. The value indicators and demand for lower carbon energy feedstocks remain very strong, and they support our continued investment and rapid expansion of Nuseed Carinata. Our ability to bring better performing genetics to the crop is delivering important gains in agronomics and yield, and that will translate to stronger economics for Nuseed and our value chain partners. In a similar way, we feel very confident in our investment in energy cane, since we have already started to expand our customer base with existing products and to focus on the value that can be generated from the successful introduction of next-generation hybrids with industry. In the immediate future, we expect to achieve further growth in both seed technology revenues and EBITDA in the second half of this financial year. As in recent years, however, seed technologies remain strongly weighted to the first half. Over time, we will start to become more balanced between halves as Omega-3 and bioenergy platforms grow with more balanced year-round revenues. Longer term, we remain committed to, and very confident, that we will meet or exceed our aspirational growth targets by 2026.

Brent Zacharias

executive
#28

Appreciate it. Greg, over to you again.

Greg Hunt

executive
#29

Yeah, thank you. Thanks, Brent. I figured it was worth giving everyone an update on how we're tracking toward our 2026 aspiration as we hit these key milestones we've laid out for ourselves. My hope is that as progress keeps coming, your confidence will build right alongside ours that we'll keep delivering. As I mentioned earlier, we've posted what I consider a strong result for the half. Our outlook for the rest of the year is positive, since we expect demand for our products to stay strong. Early trading in the second half has been encouraging, and we're still on track for modest earnings growth and constant currency underlying EBITDA for the full year. Higher plantings and favorable seasonal conditions are fueling demand for in-crop application. While manufacturers have generally reported elevated inventories, channel stocks remain relatively low—especially in North America, where we anticipate a strong second half. That gives us confidence inventories will come down over the second half and that our leverage at year-end, as Paul walked you through, will land within our targeted range. We'll keep investing in innovation and technology to create better solutions for crop protection and to pursue our growth aspirations in our Omega-3 and bioenergy platforms.

Greg Hunt

executive
#30

What we aim to do is assist our farmers in getting the most from their crop yields and in opening up new markets for what they grow, all while safeguarding the land and its natural resources for generations to come. As a dependable partner to our customers, we are steadfast in that commitment, and we stay devoted to offering inventive solutions that produce results. To sum up, our growth plan is clear. Our growth ambitions have been laid out for you, and we are on course to reach or surpass those ambitions. The year has gotten off to a very strong start, and we are on track to deliver another strong earnings result for Nufarm. With that, I will turn things back to Connie. We would be glad to take some questions.

Operator

operator
#31

Thank you. At this point I'd like to remind all of you that if you want to pose a question, you should press star followed by the number one on your phone's keypad. We'll take a brief pause so the Q&A roster can be put together. Thank you. Our first question is from Evan's line. Evan?

Evan Karatzas

analyst
#32

Yes, thank you.

Operator

operator
#33

The line is yours.

Evan Karatzas

analyst
#34

Thank you. Hello, Greg and Paul. Clearly, this was a fairly strong outcome given some rather turbulent circumstances. Would it be possible to get somewhat more detail, region by region, on what you expect for the second half? If you could perhaps address pricing and volumes, and so on.

Greg Hunt

executive
#35

Appreciate the question, Evan. So there's certainly been talk about grain prices and the way they've pulled back from their peaks — what I'd say is they're still at fairly elevated levels. Down here in Australia, expectations point to, well, another big winter crop, though perhaps not quite the size of 2022. The way I'd frame it is that our products serve as inputs, and I'm aware of the Bureau of Meteorology forecast. Our revenue really gets made when the crop goes in the ground or, you know, shortly after emergence at planting — not when harvest comes around. Like I mentioned before, demand for our products right now looks much the same as what we saw a year ago. And we'd kind of expect that, assuming conditions stay favorable, we'd land a similar kind of result in the second half of this year to what we had in the second half of 2022. Over in Europe, seasonal conditions across the Iberian Peninsula are pretty tough. It's been sitting in the middle of a drought. I noticed overnight there's been a fair amount of rain in Italy — I believe the F1 race got canceled. My hope is that some of that rain has reached areas like Spain and Portugal.

Greg Hunt

executive
#36

The remaining European regions — Central, North, and East — are, you know, performing positively. As I mentioned before, I believe trading in the second half there is likewise consistent with or a bit better than that.

Paul Townsend

executive
#37

Relative to the prior year's figure. Throughout North America, we are observing more acres being planted. We have observed — roughly 50% of the crop, as I mentioned before, is in the ground, and soil moisture levels now look quite favorable. The outlook is genuinely pointing toward a solid crop. What stands out most across North America this season is a movement out of the first half and into the second half, and we anticipate purchases occurring around June, July, and August for in-crop applications. That likely aligns more closely with the conventional pattern we saw, for instance, during financial year 2020. During 2021 and 2022, sales got pulled forward, as I believe Paul mentioned, because customers worried about locking in supply. Inventories in general remain fairly low, and we are anticipating a robust sales outcome for the second half. Regarding your question on margins, we probably will encounter some margin pressure during the second half. We anticipate the EBITA contribution will come in higher in the second half compared with the prior year, largely driven by the increase in revenues. I hope that provides a bit of a summary of the around the grounds.

Evan Karatzas

analyst
#38

Thanks for that — really useful detail. I might have one for Paul Townsend, specifically about the working capital unwind. First off, I appreciate the update on the dollar unwind through 16 May. Looking at slide 15, the total unwind for the second half has usually, or typically, come in around the AUD 300 million mark. Should we expect a comparable unwind in this second half? Is that the message you're aiming to convey, or will it perhaps be above that AUD 300 million?

Paul Townsend

executive
#39

Yeah. I suppose it truly comes down to the situation. Appreciate it, Evan. What I actually did was examine the receivables, and assuming our receivables kind of balances—if you count all days, if you will, return to typical levels—then we could anticipate something in the range of AUD 200 million to AUD 300 million from receivables alone. That's one item. That's one dimension, so to speak. That holds under the premise that the profile and collections mirror what we've seen historically. Just that qualification, but we'd expect that to hold. Regarding inventory, that's the piece that varies. It genuinely hinges on the volumes and, as we've discussed, a lot of the... Well, we... A little more detail here is that a substantial share of that volume sits in our herbicide segment, in the sense that much of the product is glyphosate and other herbicide items, which essentially means we're holding surplus volume; it truly hinges on how that sales mix shapes up in the second half. What I did highlight is that we're observing some encouraging signals, and it's simply a bit too hard to grasp—to, if you will, be highly precise about what that inventory unwind amounts to—but we're confident about the receivables component given the profile we've encountered previously.

Paul Townsend

executive
#40

That's probably more detail than you were expecting, I realize, but as a guide, that net working capital unwind could land anywhere from AUD 200 million to AUD 400 million.

Evan Karatzas

analyst
#41

Right, okay, good. That's great. At least with that AUD 600 million build in receivables, you're confident about collecting that element, that portion of it, though. Is that correct?

Paul Townsend

executive
#42

Right. Well, that's the crux of it. I think the key thing we were hoping to make clear is that — it's there on slide 16 — the AUD 550 million balance as of 30 September was genuinely abnormally low. If you look back through the history, that's the reason we laid out those other halves, simply to demonstrate how it has appeared previously, to make the point that AUD 550 is extraordinarily low.

Evan Karatzas

analyst
#43

Sure.

Paul Townsend

executive
#44

So because of that—and this is really the AUD 550 million to AUD 1.2 billion swing—that is what's behind the net working capital movement here in the first half. That was the reason for including it, Evan, simply to show that this was abnormally low, and as you can see, the current balance is very much in line with what we saw, say, in last year's first half. If you look at the balances between those two and top-line sales, they moved together, in the sense that revenue is down AUD 100 million, and receivables balances are also down AUD 100 million.

Evan Karatzas

analyst
#45

Yes. Yeah, that’s genuinely useful context. I appreciate it. I’ll share it with the team. Thank you.

Operator

operator
#46

The next question is from John Purtell. John, your line is open.

John Purtell

analyst
#47

Morning to you both, Greg and Paul. How’s everything going?

Paul Townsend

executive
#48

Alright, thank you, John.

Greg Hunt

executive
#49

Thanks, John.

John Purtell

analyst
#50

I have a few questions. Sure, we are clearly observing quite a lot of price volatility in Ag Chem, along with some normalization on the supply side compared with where things stood last year. How are you handling that price volatility? You have discussed glyphosate before, of course, but we are also seeing some weakness emerge in phenoxies and certain other ag chem grades. What sort of effect does that have on the business?

Greg Hunt

executive
#51

Well, I think the point you're making is valid. As you know, ag chem prices have fallen from the peaks we saw in 2022. In most categories, we're now observing stabilization at current levels. You pointed out that glyphosate has been the most volatile, and it has dropped from roughly U.S. $12 this time last year to about U.S. $4 today. As you're aware, we took a provision on the 31st of March here in Australia, and as I mentioned earlier, glyphosate sales are running at more normal volumes for this time of year, helped by the good rainfall across most grain-growing regions. While it's true that margins have compressed because of the declining AI price, we haven't needed to take any provisions against inventories since we're moving the inventory through. We have less glyphosate — under 60 days of cover here in Australia. We're now positioned to restock in the coming weeks at lower prices. In North America, we're seeing increased demand and sales orders in May, and we expect that, as I said earlier, to continue through June and July.

Greg Hunt

executive
#52

As you know, we would anticipate more in terms of crop over the top. Procurement arrangements we have in place cap our exposure on glyphosate in both directions, upside and downside. The point I would make, I guess, is that regarding the portfolio balance — margin, volumes, mix — that really is factored into our forecast.

John Purtell

analyst
#53

Thanks, Greg. Just a quick follow-up: clearly, Europe delivered a robust result there, and obviously there was some delayed phasing out of certain products that you mentioned. It does appear there's some indication that a number of those new product registrations and launches are starting to come through.

Greg Hunt

executive
#54

Yeah. Look, I think I'd simply point out that I'm aware there's been some anxiety regarding the portfolio and the regulatory situation in Europe. What we've observed is that we're essentially where we said we'd be. The next largest molecule we've mentioned previously is tebuconazole, and we flag that in the pack. That phaseout has now been pushed back to 2025. What matters is that the replacement product, prothioconazole, will be registered in 2024, giving us 12 months of handover. Essentially, once we reach '26, we think the revenues and margins we lose from tebuconazole will be offset by prothioconazole. As things stand today, we're really mostly past the effect of regulatory outs in Europe. It's getting harder for us to specifically call out the contribution of the Centry and Serval products, as you'd remember. From memory, the business case back then was roughly AUD 100 million to AUD 115 million of EBITDA. I'd say we would be delivering on that. It's not only the core products, it's in fact the mixture products that we've.

Greg Hunt

executive
#55

That formed part of the initial business case we were able to build out. I think we're shifting away from, you know, that anxious waiting regarding Europe toward something much more optimistic. You know, the story is beginning to change. Probably the invasion — Russia's invasion of Ukraine — has pushed part of the attention back toward food security. While, you know, we don't think there will be a meaningful departure from the Farm to Fork goals, the fact is those goals were established off the 2015, 2016, 2017 average. Regulators have in fact achieved considerable progress. I think the key thing is that, looking at our portfolio ahead, right now we're fairly comfortable that we're in a spot where our portfolio is now solid and ought to begin contributing — to our, you know, really to our earnings growth. There are certain challenges in our manufacturing operations that we flagged, and that's part of our CapEx program. When that finishes, Europe kind of lands in the same bucket as North America and Australia — namely, that your growth truly stems from the portfolio you're bringing through, or new products you can either acquire or develop and deliver alongside technology partners.

Greg Hunt

executive
#56

Compared with where we stood three years back, I feel considerably more at ease about our position in Europe right now.

John Purtell

analyst
#57

I appreciate that.

Operator

operator
#58

Richard Johnson has the next question. Richard, go ahead — your line is open.

Richard Johnson

analyst
#59

Thank you very much. Greg, may I return briefly to North America? I'm simply attempting to understand whether the shift in purchasing behavior there caught you off guard at all. I'm really considering this alongside the inventory levels, which clearly were elevated at the beginning of the year and have kept rising. I'm just trying to grasp how all of that fits together.

Greg Hunt

executive
#60

Yes, yes. That's a fair question, and I appreciate it. Going back to the full year results, at that point we were discussing how demand had been extremely strong during the first quarter — more precisely in October and November — driven by low channel inventories and the subsequent need for burn-down products. Then what took place in December was that China genuinely began to pull away from its net zero COVID stance, and as we moved through December and January, we started to observe a marked improvement in supply chains and in the capacity to supply. As a result, you also saw active ingredient prices decline. That in turn prompted the channel to essentially halt purchasing, and we have seen the effects of that right through the first half of this financial year. Normally, in North America, it is around this point in the year when demand picks up, especially for glyphosate and herbicide products, since those get applied in the crop. What occurred in 2021 and 2022 was that those sales got pulled forward, so customers were confident they already had the product on hand.

Greg Hunt

executive
#61

What we're really witnessing at this point is a shift back to more conventional ways of doing things. Let me say it once more: we would expect to see—and indeed we are already seeing—significantly stronger demand as the channel begins restocking. Keep in mind that the crop has only just gone in the ground, really. The way it works is that as the crop develops and weed pressure builds, so we're genuinely talking about May now, let's say June, July—you'd anticipate considerably stronger sales in June and July, applied over the top of the crops. That's a more traditional pattern, and if you look back at 2019 and 2020, that is in fact what happened. I hope that addresses the question.

Richard Johnson

analyst
#62

Yes, that definitely helps—thanks, Greg. I did notice the remark about the pipeline’s value staying more or less the same as it was when you first shared your aspirational targets. I haven’t worked out what the burn rate has been, but does that imply those targets—or your confidence in them—have gone up, or that the even longer-term outlook is stronger than it would have been when you initially assembled them?

Greg Hunt

executive
#63

Once more, I appreciate the question. There’s quite a thorough slide available—for anyone on the call, please pull up that slide, which lays out the pipeline, spanning numerous years, numerous segments, and numerous crops. Rico, perhaps you could address what has shifted relative to what we showed you back in November 2022 and the update we gave at full view last year. Thank you, Rico.

Rico Christensen

executive
#64

Certainly. Thank you, Greg. Now, if everyone could pull up the slide showing the pipeline overview, you'll see a few useful markers that should make it easier to follow along. First, for every active project where we've made progress, we've placed a small green chevron beside the advancement, and that shows what has changed compared with the same slide we shared back in February 2022. Another change, as we mentioned on our earlier call, is that a number of projects have been successfully closed. Those have been taken out, since they're no longer part of the pipeline—they're actual commercial products now. In their place, we've added several new ones. For those additions, we've marked them with a small asterisk as well as a green star over on the right-hand side. That should help you work your way through the slide and spot what's new. We've also revised certain launch years according to what we've observed, and you'll see that for some of them we've actually brought the launch years forward. All of that is very encouraging. One point I'd like to emphasize: we have consistently noted that these projects represent merely a subset of the projects we hold.

Rico Christensen

executive
#65

That isn't the entirety of our pipeline. Actually, the number of projects we have exceeds what this slide displays. We made that point clear at Investor Day in 2022, and I'm stressing it again right now. I hope that addresses what you asked.

Richard Johnson

analyst
#66

That does help. Thank you so much. I'm not sure whether Brent is still on the line, but I have a couple of simple questions regarding seeds.

Greg Hunt

executive
#67

Absolutely, happy to.

Rico Christensen

executive
#68

Are you still there, Brent?

Richard Johnson

analyst
#69

Thank you, Brent. First, I’d like to know how foreign exchange affected your results during the first half. Second, could you remind me—or perhaps say a bit—about how seasonality works in this business?

Brent Zacharias

executive
#70

Yeah, absolutely. FX isn't really a big factor for us, since we operate across multiple geographies and have a very strong business based in Australia. When you look at constant currency analysis, it truly doesn't have much impact. I think that covers the first part of your question, Richard. On the second one, regarding seasonality — since we grow spring crops up in the northern hemisphere and winter crops down in the southern hemisphere, we're very heavily weighted toward the first half. That remains true for a lot of our core seeds business. We've still got more season ahead of us, really through the first couple months of our second half, and trading results over the last six weeks have continued to be pretty strong. As I think we called out, the other thing that's beginning to shift, of course, is that our Omega-3 and bioenergy businesses are becoming more year-round operations. We're starting to see a bit more contribution coming from those into the second half. We're still going to be fairly heavily weighted to the first half, but as Greg called out, we'd probably expect a slightly stronger second half than what we had the year before.

Richard Johnson

analyst
#71

Understood — that’s quite useful. Many thanks. I have nothing further.

Brent Zacharias

executive
#72

Appreciate that, Richard.

Operator

operator
#73

The following question is from Jonathan Snape. Jonathan, you may go ahead.

Jonathan Snape

analyst
#74

Yes, hello, and thanks. Is my audio coming through clearly for everyone?

Paul Townsend

executive
#75

Yes, Jonathan, I can hear you perfectly.

Jonathan Snape

analyst
#76

Thank you. Paul, perhaps the first question is about working capital. I know we enjoy disagreeing about those off-balance-sheet facilities. It seemed as though in the first half it was a considerable drag on your cash flow — that is, you appeared to use it, to utilize it, much less than 1 year earlier, when it was probably a positive contributor to cash flow, whereas now it looks like it was a fairly material negative contributor to cash flow across the 6 months. Is there any specific reason that figure fell so substantially?

Paul Townsend

executive
#77

Right, it's fairly straightforward — since we aren't placing orders, we aren't drawing on the supplier financing facility. Your payables are declining.

Jonathan Snape

analyst
#78

All right.

Paul Townsend

executive
#79

Our stock levels are more than sufficient.

Jonathan Snape

analyst
#80

Alright. Okay. Yeah. May I just ask — I believe on the prior call you provided guidance that D&A would be broadly consistent with 2022, or not materially different. Does that still hold? I wasn't able to locate anything about it in the deck.

Paul Townsend

executive
#81

No, that’s a reasonable thing to ask. Since the product registrations have slipped, that has essentially caused a drop, or a cut, in how we amortize intangibles, along with CapEx running behind schedule. We had anticipated spending more on the product than we actually have. Our guidance was similar to FY22. At this point it truly hinges on how our CapEx spending pattern shapes up during the second half, Jonathan. That is the reason we have intentionally stayed quiet. I would say it will come in below last year, given what I’d describe as the delayed situation.

Jonathan Snape

analyst
#82

Alright, Brent, I’d like to ask about Omega-3. One of your largest competitors in that area — at least within agri — reported quite substantial price growth, above 30%, based on what I saw in their second-quarter results. You’ve mentioned some shifts elsewhere, I believe, but from what I can tell, pricing growth is in the double digits across probably every category you compete in. I realize you’re working to enter that sector. Given the jump over the last 12 months, are you seeing more inbound inquiries for your product?

Brent Zacharias

executive
#83

Sure. What I'd say is that, at the moment, demand for AquaTerra is really robust. We've had encouraging signs when it comes to broadening our market in Chile. As I noted, we've begun expanding in North America, and then, of course, there are the remarks about the possibility of securing approval in Norway. Yes, demand looks very strong. I think that's especially true as the industry watches fish oil supply tighten, and this news over the last 48 months — sorry, the last 48 hours — will likely drive that even further. Fish oil prices have been climbing, as I'm sure you're tracking too. From where we sit, the market on the demand side is quite strong. We anticipate that continuing, particularly since customers are also recognizing the fish health benefits and sustainability advantages our product offers. Yes, we're quite happy with how the market is shaping up.

Jonathan Snape

analyst
#84

Perhaps just a single question about Carinata, since, you know, you've mentioned that you're beginning to sell through it, but the carbon credits come in the second half, correct? You'd anticipate some kind of profitability emerging from that. Could it be that the seeds business, instead of losing money, reaches breakeven at an EBIT level thanks to that contribution? I mean, I realize you've stated there's an improvement, but is it that significant, or not really?

Brent Zacharias

executive
#85

My apologies — I just want to be certain I've got your question right, Jonathan, regarding our.

Jonathan Snape

analyst
#86

Well, the carbon credit sales are coming through.

Brent Zacharias

executive
#87

Mm-hmm.

Jonathan Snape

analyst
#88

During the latter six months of this year, we anticipate the initial batch, which ought to contribute positively. I'm merely attempting to grasp how significant...

Brent Zacharias

executive
#89

Yeah, I’d put it this way in the...

Jonathan Snape

analyst
#90

That falls within the second-half thinking process.

Brent Zacharias

executive
#91

My sense is that the Carinata advantages will likely show up more in the back half for us. We do anticipate that it will add to our EBITA growth during that second half, if that helps, Jonathan.

Jonathan Snape

analyst
#92

Yeah. Okay, thanks.

Operator

operator
#93

James Ferrier has the next question in the queue. James, your line is now open.

James Ferrier

analyst
#94

Thank you. Good morning, gentlemen. I appreciate you making time for this. Brent, since you have the floor, maybe I'll start with you. Broadly speaking, as we consider both Omega-3 and the bioenergy programs, I'm curious about how material their combined contribution to the P&L actually is. Of course, there are SG&A costs involved, as Paul mentioned, since some of those programs are still in a development phase. Taken together, what kind of financial contribution do they make within the seeds business? Clearly the legacy business on its own delivered an exceptionally strong result.

Brent Zacharias

executive
#95

Right, so what I’d say is that yes, the seed platform delivered a strong result, as I noted in my remarks. Revenue and margin both grew in Omega-3 and in our bioenergy segments too. They remain a fairly small contributor at the half, and as we’ve signaled previously, we expect much more meaningful contributions from those platforms in 2024, 2025 and 2026. At the half, they are still relatively small contributors, but growing. For perspective, probably a little under AUD 10 million in revenues in each of those platforms.

James Ferrier

analyst
#96

Yeah, got it. Thanks. For the second question, Greg, this is probably one for you to begin with, though I'm sure Paul may want to jump in too. If we look back at FY 2022 and group revenue, it was mostly about pricing. I believe your remarks then were that, in aggregate across the group, there was, you know, fairly modest volume growth. Now, with this first half result in front of us, could you give some references or observations around how price and volume were mixed?

Paul Townsend

executive
#97

Thanks, James. The change is driven more by mix and price than by volume. Volume has taken a hit, and you can see that in our inventory balances, since we really haven't managed to move a lot of the high-volume herbicide products. Volume is down. Product mix has clearly gotten better, and that comes from the shift away from the herbicide. There's also a bit of price in there, because we've faced cost pressures in manufacturing on input costs, plus some manufacturing underrecoveries tied to the CapEx programs we have in place, Wyke in particular. That's putting some pressure on margins too, but we can recover it through price. Mix would be the majority, though there is a price element that covers some of these costs. Volume is down because of that mix factor, I suppose, and our inventory balances reflect it. James, perhaps I can just add to that. At the full year results, we talked about earnings being weighted to the first half. We said in 2022 that it was 75% first half, 25% second half. At the full year, I think we said our forecast for this year would be closer to 65%-35%, which is what we saw in 2021.

Paul Townsend

executive
#98

My current expectation is that it will land nearer to 70%/30%. That really mirrors the stronger half-year performance and the higher sales. In the second half, you'll likely see volumes affected somewhat by margin pressure. That's how I'd suggest looking at it.

James Ferrier

analyst
#99

Yes, that helps a lot, and it probably sets up the last question I have, Greg. On that margin pressure you mentioned, your earlier remarks raised that concern really only in connection with North America. First, I'm curious: within North America, does it come from agriculture or from turf and ornamental? And why North America alone? Why is it that you don't share those same concerns in the other regions?

Paul Townsend

executive
#100

Okay, so North America — especially on glyphosate, and as I attempted to point out — we're seeing demand for over-the-top applications in the second half. That's the basis for my remarks about stronger sales volumes in the second half. Like I mentioned, tolling agreements are in place, and they cap both the upside and the downside. Another thing is that we've been purchasing some products — not much over recent weeks — but we have restocked in North America at lower prices. That's partly why, across the balance of the portfolio, and in particular our own phenoxy products, I don't have a concern. In Australia, we've really brought stocks down, especially glyphosate. We essentially took a provision at this time last year, since we could see prices were going to fall — and that's what happened, and they've kept coming off.

Greg Hunt

executive
#101

Right now in Australia we're moving glyphosate with thin margins. Like I mentioned, our cover is likely under 60 days. Regarding the rest of the portfolio, I don't share those same worries. The remainder of our portfolio hasn't shown the volatility that glyphosate has. As I noted, glyphosate went from $14 a kilo around this time last year to roughly $4 currently. We haven't seen anything close to that kind of volatility across the rest of our portfolio.

James Ferrier

analyst
#102

Got it, Greg. And just probably, lastly, on your remark about the ag market, North America compared with TNO.

Greg Hunt

executive
#103

My apologies — you're correct. In North America, there are really 3 markets worth considering. First is Canada, where we hold exclusive distribution rights for Sumitomo products, and that tends to be a segment with higher margins for us. Demand through turf and ornamental looks pretty good, so margins there are definitely holding up. The genuine squeeze is in the broadacre crop protection market — that's probably the clearest way to put it. Then in the U.S., where, as I mentioned, manufacturers are carrying higher inventories, and our competitors have reported that widely. Again, I'd simply underline that channel inventories remain relatively low. We'll see over the coming few months — the coming few weeks, really — but certainly within this financial year, the channel will begin restocking. That gives us the chance, as we've been saying, to bring inventories down and cut working capital to the levels we've discussed by the close of this financial year.

James Ferrier

analyst
#104

Yes. Got it. To put a fine point on it, we’re carrying a sizable seasonal inventory balance at the moment. You feel good about the pace at which it’s clearing while prices are declining, and about your position with regard to higher inventory levels — glyphosate in North America, for instance — where you’re basically acting as a pass-through, so the chance of that affecting your margins is negligible.

Greg Hunt

executive
#105

Well, I wouldn't put it as being happy. I'd describe it as comfortable. What I'd tell you is that, you know, I'd anticipate the overall effect will have an impact — there's no question about that. What I'm getting at is that I don't think it will be material, and it's definitely baked into our forecasts.

James Ferrier

analyst
#106

Excellent. I appreciate that. Thanks.

Greg Hunt

executive
#107

Connie —

Operator

operator
#108

There aren't any—

Greg Hunt

executive
#109

It looks like we’ve reached the end of the questions.

Operator

operator
#110

Alright, we have no more questions right now. I’ll hand the call back over to Greg. Thank you.

Greg Hunt

executive
#111

All right, thank you. Thank you, Connie. Once more, I appreciate everyone being with us today. I realize we'll be speaking with several of you during the coming 2 days and at the start of next week. I'm eager to connect with you then. My thanks go to Brent for being with us from Calgary, and to Rico as well. As I mentioned, I anticipate sharing an update with you at some point between now and the full year. Many thanks once again.

Operator

operator
#112

That wraps up the call for today. You're free to disconnect at this point. Thanks, everyone.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Nufarm Limited transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Nufarm Limited earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nufarm Limited or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.